These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 8033145)

  • 21. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
    Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
    McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
    Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
    Guichard S; Montazeri A; Chatelut E; Hennebelle I; Bugat R; Canal P
    Clin Cancer Res; 2001 Oct; 7(10):3222-8. PubMed ID: 11595718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
    Goddard P; Valenti M; Kelland LR
    Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumour activity of cis-diamminedichloroplatinum (II) against human tumour xenografts depends on its area under the curve in nude mice.
    Kurihara N; Kubota T; Hoshiya Y; Otani Y; Watanabe M; Kumai K; Kitajima M
    J Surg Oncol; 1996 Feb; 61(2):138-42. PubMed ID: 8606546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
    Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
    Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
    Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
    Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
    Anticancer Drug Des; 1994 Dec; 9(6):495-509. PubMed ID: 7880375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
    Marcantonio D; Panasci LC; Hollingshead MG; Alley MC; Camalier RF; Sausville EA; Dykes DJ; Carter CA; Malspeis L
    Cancer Res; 1997 Sep; 57(18):3895-8. PubMed ID: 9307267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
    Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
    Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)].
    Sova P; Chladek J; Zak F; Mistr A; Kroutil A; Semerad M; Slovak Z
    Int J Pharm; 2005 Jan; 288(1):123-9. PubMed ID: 15607264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
    Staffhorst RW; van der Born K; Erkelens CA; Hamelers IH; Peters GJ; Boven E; de Kroon AI
    Anticancer Drugs; 2008 Aug; 19(7):721-7. PubMed ID: 18594214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antitumor effects of newly synthesized analogues of platinum (NK121) and bleomycin (NK313) in nude mice implanted human tumor].
    Yokoe H; Kanazawa H; Takahashi K; Sato K
    Gan To Kagaku Ryoho; 1991 Jan; 18(1):97-101. PubMed ID: 1702964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
    Zhao L; Ching LM; Kestell P; Baguley BC
    Clin Cancer Res; 2003 Dec; 9(17):6545-50. PubMed ID: 14695159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
    Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of N1,N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action.
    Porter CW; Bernacki RJ; Miller J; Bergeron RJ
    Cancer Res; 1993 Feb; 53(3):581-6. PubMed ID: 8425191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.